E-therapeutics Share Discussion Threads

[ali47fish] 26/10/2023 07:52

the numbers are down

[ali47fish] 17/10/2023 09:52

why does' nt the company say something with the share price continually falling- what has changed apart from the macro factors

[ali47fish] 28/9/2023 15:30

a mistake sorry!

[1347] 28/9/2023 15:00

What'a this got to do with ETX?

[maccamcd] 28/9/2023 07:24

Rathbone /investec wealth merger change of ownership

[jpuff] 26/9/2023 12:04

Oh dear if Griff's involved then that's probably the kiss of death after being in deep matter myself too

[maccamcd] 25/9/2023 13:42

Did you listen in on the investor meet presentation a few months ago?I believe it's been mainly one retail investor who's been selling bits continuously...Annoying, but I hope his colour about the opportunity plays out vs one retail seller doing the damage in a tightly held share

[1347] 25/9/2023 13:06

Do ETX do anything, or have they become just another placings today, jam tomorrow company? I hope it's not going the same way as DeepMatter, it was a disgrace what happened there and I note Griff is involved in both. Ali needs to get his finger out and let shareholders know what they are doing, if anything.

[ali47fish] 25/9/2023 08:30

what 's happening here-keeps falling by chunks

[maccamcd] 20/9/2023 07:53

neutral I've been told. nothing to read into

[ali47fish] 20/9/2023 07:30

dont understand this change at the top- good or bad

[jpuff] 15/9/2023 15:31

Sinking fast - what's up?

[ali47fish] 11/9/2023 07:18

wrong site sorry

[ali47fish] 07/9/2023 21:20

exercise of option doest say by whom

[ali47fish] 23/8/2023 10:16

ok so normally market makers control the spread- what is the company doing to help? no news for a while!

[maccamcd] 23/8/2023 09:46

which is wide.. nearly 10% spread

[ali47fish] 23/8/2023 09:26

from london sth east the spread is normal-Bid: 15.50; Ask: 16.95

[maccamcd] 23/8/2023 08:36

spread is wide.. 107 shares only traded bid side

[ali47fish] 23/8/2023 08:06

why is this retracing

[maccamcd] 15/7/2023 09:47

Morgan Stanley, an investment bank, reckons that within a decade the pharmaceutical industry may be spending $50bn a year on AI to speed up drug development. Most of the buzz revolves around AIs trained on biological data that could improve the hit-and-miss process of drug discoveryhttps://acrobat.adobe.com/id/urn:aaid:sc:EU:c32cb246-deff-4aa4-ae06-775fdd7935b0https://www.economist.com/business/2023/07/13/big-pharma-is-warming-to-the-potential-of-ai

[maccamcd] 13/7/2023 12:28

yeah.. bit of demand. spread wide

[dplewis1] 13/7/2023 11:18

Nice spot macca, could be behind todays rise?

[maccamcd] 13/7/2023 11:01

Have you all seen this news???

Recursion Pharmaceuticals (RXRX.NQ) strikes computational drug discovery deal with Nvidia (NVDA.NQ).
• Recursion Pharmaceuticals, an AI drug discovery business, announced a collaboration and $50m equity investment by Nvidia.
• Under the agreement, the partners aim to use Recursion’s biological and chemical datasets to accelerate the training of computational models on Nvidia’s platform.
• These models could be used for commercial license/release on BioNeMo, NVIDIA’s cloud service for generative AI in drug discovery.
• Recursion also expects to use this software to support its internal pipeline and its current and future partners.
The agreement demonstrates the continued interest of generative AI in drug discovery. BioNeMo incorporates large language models (LLMs) into its platform. LLMs, such as Chat GPT-4, are a type of AI trained on large datasets to perform a wide range of tasks, such as generating new hypotheses, predicting protein-protein interactions as well as analysing biomedical literature and patent information at scale.
Although LLMs show promise in improving drug discovery activities, few companies have integrated this technology into their operations. The slow adoption of LLMs in the pharmaceutical industry leaves a significant opportunity for first movers to capture interest in this area. On AIM, ETX is integrating Large Language Models (LLMs) into its own platform.